NextCure’s Promising Trajectory: Buy Rating Backed by Clinical Progress and Competitive Edge

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on NextCure (NXTC – Research Report). The associated price target is $3.00.

Emily Bodnar has given her Buy rating due to a combination of factors including the progress in NextCure’s clinical trials and the competitive landscape of their B7-H4 ADC program. The completion of Cohort 1 in the Phase 1 trial for LNCB74 and the ongoing enrollment of Cohort 2 suggest a positive safety profile, as no dose-limiting toxicities have been observed. This progress indicates a promising trajectory for the drug’s development.
Furthermore, despite the competitive nature of the B7-H4 ADC landscape, NextCure’s LNCB74 has shown superior efficacy in preclinical models compared to similar constructs, particularly in ovarian and breast cancer. The proprietary glucuronidase linker technology used in LNCB74, developed with LigaChem, enhances its potential effectiveness. These factors, combined with the discontinuation of a competitor’s program, position NextCure favorably in the market, justifying the Buy rating.

According to TipRanks, Bodnar is an analyst with an average return of -4.4% and a 27.24% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as AnaptysBio, Imunon, and Jasper Therapeutics.